Cargando…
Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis
BACKGROUND: Methotrexate (MTX) is widely used and considered a first-line disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). However, 10% to 30% of patients discontinue therapy within a year of starting the treatment, usually because of undesirable side effe...
Autores principales: | Qiu, Qi, Huang, Jing, Lin, Yang, Shu, Xiaoming, Fan, Huizheng, Tu, Zhihua, Zhou, Youwen, Xiao, Cheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369916/ https://www.ncbi.nlm.nih.gov/pubmed/28296761 http://dx.doi.org/10.1097/MD.0000000000006337 |
Ejemplares similares
-
Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis
por: Qiu, Qi, et al.
Publicado: (2017) -
Fusion proteins of biologic agents in the treatment of rheumatoid arthritis (RA): A network meta-analysis
por: Wu, Mingcai, et al.
Publicado: (2021) -
Dietary fiber intake associated with risk of rheumatoid arthritis among U.S. adults: NHANES 2010-2020
por: Liu, Li, et al.
Publicado: (2023) -
Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy
por: Taylor, Peter C., et al.
Publicado: (2022) -
Patterns and trends of primary drug-resistant tuberculosis in Chongqing, China, from 2012 to 2020
por: Zhang, Huizheng, et al.
Publicado: (2023)